Clinical trial to compare availability in the body of the active substance nicotine as well as patch adhesion of the newly developed patch LTS Nicotine TTS vs. Nicotinell® (21 mg/24 h) in healthy smokers after single patch application

2023-503548-14-00 Protocol LTS 01/23 Human pharmacology (Phase I) - Bioequivalence study Ended

Start 30 Sep 2024 · End 15 Nov 2024 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol LTS 01/23

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Bioequivalence study
Status Ended
Participants planned 30
Countries 1
Sites 1

bioequivalence and patch adhesion trial; therapeutical indication not studied

Key facts

Sponsor
LTS LOHMANN Therapie-Systeme AG
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Psychiatry and Psychology [F] - Behavior and Behavior Mechanisms [F01]
Trial duration
30 Sep 2024 → 15 Nov 2024
Decision date (initial)
2023-05-22
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

bioequivalence and patch adhesion trial; therapeutical indication not studied

VersionLevelCodeTermSystem organ class
20.0 PT 10057852 Nicotine dependence 100000004873
20.0 LLT 10008374 Cessation of smoking 10041244
20.0 PT 10053325 Smoking cessation therapy 100000004865

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

LTS LOHMANN Therapie-Systeme AG

Sponsor organisation
LTS LOHMANN Therapie-Systeme AG
Address
Lohmannstrasse 2
City
Andernach
Postcode
56626
Country
Germany

Scientific contact point

Organisation
LTS LOHMANN Therapie-Systeme AG
Contact name
Corporate Vice President, Head of Pharmaceutical Development II R&D

Public contact point

Organisation
LTS LOHMANN Therapie-Systeme AG
Contact name
Corporate Vice President, Head of Pharmaceutical Development II R&D

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ended 30 1
Rest of world 0

Investigational sites

Germany

1 site · Ended
SocraTec R&D GmbH Clinical Pharmacology Unit
CPU, Mainzerhofplatz 14, 99084, Erfurt

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2024-09-30 2024-11-15 2024-10-01 2024-10-15

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-03-28 Germany Acceptable
2023-05-19
2023-05-22
2 SUBSTANTIAL MODIFICATION SM-1 2024-07-19 Germany Acceptable
2024-08-23
2024-08-23
3 NON SUBSTANTIAL MODIFICATION NSM-1 2024-09-26 Germany Acceptable
2024-08-23
2024-09-26